<DOC>
	<DOCNO>NCT00130208</DOCNO>
	<brief_summary>The purpose study determine whether treatment sulodexide effective reduce level urine albumin excretion patient early diabetic kidney disease express microalbuminuria .</brief_summary>
	<brief_title>Effect Sulodexide Early Diabetic Nephropathy</brief_title>
	<detailed_description>Diabetic nephropathy important cause morbidity mortality patient either type 1 type 2 diabetes mellitus . The pathogenesis natural history diabetic nephropathy characterize initially microalbuminuria follow progressive decline glomerular function . An emerge body evidence support notion glomerular capillary wall mesangial alteration diabetic nephropathy involve pathobiochemical alteration glycoproteins structure . Evidence , experimental animal render diabetic , reveals administration heparin anionic glycoprotein ( GAG ) effectively prevent biochemical alteration responsible albuminuria . Sulodexide , orally active agent anticoagulant property associate oral dose range , comprise three naturally occur glycosaminoglycan ( GAG ) polysaccharide component isolated porcine intestinal mucosa . Small clinical study employ sulodexide , show albuminuria significantly diminish patient diabetic nephropathy , even patient receive angiotensin II receptor blocker ( ARB ) angiotensin convert enzyme inhibitor ( ACEI ) , agent already proven reduce albuminuria slow progressive diabetic nephropathy . This study design evaluate whether sulodexide safe effective treating subject type 2 diabetic nephropathy . Subjects type 2 diabetes microalbuminuria ( define urinary albumin creatinine ratio , ( ACR ) men 35-200 mg/G woman 45-200 mg/G ) also receive either irbesartan 300 mg/day , losartan 100 mg/day , maximum approve dose angiotensin receptor blocker ( ARB ) angiotensin convert enzyme inhibitor ( ACEI ) enrol study . The study consist follow period : - Screening : 1-2 week assess basic eligibility/exclusion criterion - Run-in : 16 week maximal dose ARB ACE stable blood pressure control - Qualifying visit : qualifying patient maximal dose ARB ACE minimum 4 month stable BP control , SBP &lt; 150 mmHg , DBP &lt; 90 mmHg albumin creatinine ratio , ( ACR ) men 35-200 mg/G woman 45-200 average 3 first morning void - Randomization : patient randomize sulodexide 100 mg match placebo administer orally twice day . - Maintenance : 26 week maintenance period , 4 visit monitor safety ACR - Washout Period : 8 week washout period , 2 visit monitor safety ACR</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
	<criteria>Diagnosis type 2 diabetes Serum creatinine equal less 1.5 mg/dL Microalbuminuria , define urine albumin/creatinine ratio men ; 35 200 mg albumin/G creatinine , woman ; 45200 mg albumin/G creatinine Blood pressure control less 150/90 mmHg Willing change antihypertensive medication regimen necessary Age onset type 2 diabetes &lt; 18 year ; HbA1C &gt; 10.0 % ; Morbid obesity define body mass index ( BMI ) &gt; = 45 kg/m2 ; Type 1 ( insulindependent ; juvenile onset ) diabetes ; Renal disease follow : Patients know nondiabetic renal disease Renal allograft Absolute requirement combination therapy angiotensin convert enzyme inhibitor ( ACEI ) angiotensin receptor blocker ( ARB ) ; Cardiovascular disease follow : Unstable angina pectoris within 3 month study entry ; Myocardial infarction , coronary artery bypass graft surgery , percutaneous transluminal coronary angioplasty stent placement within 3 month study entry ; Transient ischemic attack within 3 month study entry ; Cerebrovascular accident within 3 month study entry ; Symptomatic heart failure require ACE inhibition ; New York Heart Association Functional Class III IV heart failure ; Obstructive valvular heart disease hypertrophic cardiomyopathy ; Second third degree atrioventricular block successfully treat pacemaker Need chronic ( &gt; 2 week ) immunosuppressive therapy , include corticosteroid ( exclude inhale nasal steroid ) ; History multiple drug allergy ; New diagnosis cancer recurrent cancer within 5 year screen ( ( except nonmelanoma skin cancer ) ; Psychiatric disorder interfere patient 's ability comply protocol ; Inability tolerate oral medication history significant malabsorption ; Inability remain stable dose follow class medication 30 day prior randomization throughout study : 3hydroxy3methylglutarylcoenzyme A ( HMGCoA ) reductase inhibitor ( statin ) ; Peroxisome proliferatoractivated receptor gamma ( PPAR gamma inhibitor ( glitazones ) ; Cyclooxygenase2 inhibitor ( COX2 inhibitor ) ; Nonsteroidal antiinflammatory drug ( NSAIDS ) ; History alcohol drug abuse within 12 month study entry ; Known human immunodeficiency virus ( HIV ) disease ; Any medical condition render patient unable unlikely complete study , would interfere optimal participation study produce significant risk patient ; Receipt investigational drug ( include placebo ) within 30 day enrollment ; Evidence hepatic dysfunction include total bilirubin &gt; 2.0 mg/dL liver transaminase ( AST ALT ) &gt; 3 time upper limit normal ; Anticipated surgery within trial period ; Inability cooperate study personnel history noncompliance medical regimen ( i.e. , patient would expect comply poorly treatment ) ; Known allergy intolerance heparinlike compound ; Untreated urinary tract infection would impact urinary protein value ; Prior exposure sulodexide , either clinical setting participant another clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Albuminuria</keyword>
	<keyword>Diabetic Nephropathy</keyword>
</DOC>